LFWD · XBRL financial data
Lifeward financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (LFWD's year ends in late December)
- † Share count changed about 1/7 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (LFWD's year ends in late December)
- † Share count changed about 1/7 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (LFWD's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | †Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (7,531) | (5,639)* | (6,276) | (4,304) | (3,084) | (15,278)* | (4,834) | (6,562) | (3,170) | (5,348)* | (10,793) | (11,519) |
| Stock-based compensation | 333* | 373* | 381 | 376* | 290* | 234* | 220 | 182* | 174* | 167* | 177 | 262* |
| Net cash from operating activities | (7,444)* | (4,484)* | (7,673) | (5,617)* | (4,459)* | (3,969)* | (5,493) | (3,936)* | (3,842)* | (3,555)* | (3,675) | (6,005)* |
| Purchases of property and equipment | 2* | 79* | 0 | 0* | 0* | 0* | 5 | 0* | 0* | 11* | 0 | 8* |
| Net cash from investing activities | (18,070)* | (79)* | 0 | 0* | 0* | 0* | (5) | 0* | 0* | (11)* | 6,500 | (28)* |
| Net cash from financing activities | (6)* | 0* | 0 | 0* | 0* | 0* | 4,471 | 3,308* | 646* | 3,778* | 6,422 | 4,083* |
| Net change in cash | (25,549)* | (4,494)* | (7,688) | (5,617)* | (4,473)* | (3,906)* | (1,020) | (565)* | (3,163)* | 219* | 9,250 | (1,941)* |
- † Share count changed about 1/7 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Lifeward | 9,448 | 6,623 | (6,005)* | 2.8M | 1.6 quarters | 10-QJun 30, 2026 |
| Co-Diagnostics | 3,650 | 166 | (7,153)* | 6.3M | 0.5 quarters | 10-QJun 30, 2026 |
| Mountain Crest Acquisition Corp. V | 18 | not reported | (79)* | 2.9M | 0.2 quarters | 10-QJun 30, 2026 |
| Guided Therapeutics | 12 | 0 | (319)* | 96.5M | 0.0 quarters | 10-QJun 30, 2026 |
| Medinotec | 2,584 | 3,201 | 108* | 11.8M | — | 10-QAug 31, 2026 |
| Nexgel | 1,706 | 3,686 | (2,197)* | 9.7M | 0.8 quarters | 10-QJun 30, 2026 |
| Lyra Therapeutics | 15,893 | 7* | (6,066)* | 1.8M | 2.6 quarters | 10-KDec 31, 2025 |
| Semler Scientific | 10,176 | 7,491 | (32,950)* | 15.2M | 0.3 quarters | 10-QSep 30, 2025 |
| Intelligent Bio Solutions | 3,992 | 1,146* | (3,182)* | 3.0M | 1.3 quarters | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.